Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities

Michael Raymond Binder

doi:doi:10.11648/j.ajim.20221006.11

| Peer-Reviewed

Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities

Michael Raymond Binder

Published in American Journal of Internal Medicine (Volume 10, Issue 6)

Received: 17 October 2022 Accepted: 2 November 2022 Published: 10 November 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The anticonvulsant gabapentin is now one of the most commonly prescribed drugs in America. However, after nearly three decades of steady growth in popularity, the drug is becoming as controversial as it is popular. Although gabapentin was initially approved for the adjunctive treatment of partial seizures, its use has gradually expanded to an ever-increasingly number of disorders, including neuropathic pain, restless leg syndrome, generalized anxiety disorder, bipolar disorder, treatment-resistant depression, post-traumatic stress disorder, chronic insomnia, various substance use disorders, chronic insomnia, diabetic neuropathy, postoperative analgesia, tension headache, migraine headache, fibromyalgia, irritable bowel syndrome, hot flashes, essential tremor, nausea and vomiting, interstitial cystitis, overactive bladder, pruritus, chronic cough, and persistent hiccups. However, in addition to its prescription use, gabapentin is now becoming increasingly popular among illicit users, a phenomenon that appears to be the primary basis of the growing controversy around the drug. This article will explore both the benefits and liabilities of gabapentin in an effort to dispel the myths and clarify the facts about the drug. It will also compare the benefits of gabapentin to other anticonvulsants, analgesics, and psychotropic drugs in an effort to arrive at a more accurate risk-benefit assessment of gabapentin’s use. With an ever-increasing amount of information being uploaded to the internet, it is especially important for those who have the most experience prescribing and researching gabapentin to tease out the misinformation and provide the medical community and the public with the most accurate possible understanding of the drug. Only then will we be able to take the greatest advantage and avoid the most harm in relation to this inexpensive and widely-prescribed pharmacological resource. Those interested in addition evidence-based information on gabapentin are directed to the article, Gabapentin: The Popular but Controversial Anticonvulsant Drug May Be Zeroing in on the Pathophysiology of Disease.

Published in	American Journal of Internal Medicine (Volume 10, Issue 6)
DOI	10.11648/j.ajim.20221006.11
Page(s)	114-121
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Gabapentin, Neurontin®, Anxiety, Mood Swings, Chronic Pain, Drug Withdrawal, Neuronal Hyperexcitability, Mood Stabilizers

References

[1]	Binder MR. Mind-Brain Dynamics in the Pathophysiology of Psychiatric Disorders. AJPN 2022; 10 (2): 48-62.
[2]	Modesto-Lowe V, Barron GC, Aronow B, Chaplin M. Gabapentin for alcohol use disorder: A good option, or cause for concern? Cleveland Clinic Journal of Medicine 2019; 86 (12): 815-823.
[3]	van Hooft JA, Dougherty JJ, Endeman D, Nichols RA, Wadman WJ. Gabapentin inhibits presynaptic Ca (2+) influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002; 449 (3): 221-28.
[4]	Taylor CP. Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997; 153 Suppl 1: S39-45.
[5]	Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs 2018; 27 (1): 113–124.
[6]	Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. JAMA 1998; 280: 1837-1842.
[7]	Binder MR. The multi-circuit neuronal hyperexcitability hypothesis of psychiatric disorders. AJCEM 2019; 7 (1): 12-30.
[8]	Binder MR. Neuronal hyperexcitability: significance, cause, and diversity of clinical expression. AJCEM 2021; 9 (5): 163-173.
[9]	Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician 2000; 61 (8): 2437-2444.
[10]	Kappuzzo KA. Treatment of postherpetic neuralgia: focus on pregabalin. Clin Interv Aging 2009; 4: 17-23.
[11]	Singh L, Field MJ, Ferris P, et al. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 1996; 127 (1): 1-9.
[12]	Markota M, Morgan RJ. Treatment of generalized anxiety disorder with gabapentin. Case Rep Psychiatry 2017; 2017: 6045017.
[13]	Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20 (4): 467-471.
[14]	Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19 (4): 341-348.
[15]	Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13 (3): 141-146.
[16]	Sokolski KN, Green C, Maris DE, DeMet EM. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 1999; 11 (4): 217-222.
[17]	Gabriel A. Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study. Dovepress 2010; 2010: 6 (1): 711-717.
[18]	Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, Price LH. Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review. J Affect Disord 2001; 63 (1-3): 243-247.
[19]	Perloff MD, Berlin RK, Gillette M, Petersile MJ, Kurowski D. Gabapentin in headache disorders: What is the evidence? Pain Medicine 2016; 17 (1): 162–171.
[20]	Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41 (2): 119-128.
[21]	Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56 (4): 1336-1344.
[22]	Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22 (10): 981-988.
[23]	van de Vusse AC, Stomp-van den Berg SGM, Kessels AHF, Weber WEJ. Randomised controlled trial of gabapentin in complex regional pain syndrome type 1 [ISRCTN84121379] BMC Neurol 2004; 4: 13.
[24]	Allameh Z, Rouholamin S, Valaie S. Comparison of gabapentin with estrogen for treatment of hot flashes in post-menopausal women. J Res Pharm Pract 2013; 2 (2): 64–69.
[25]	Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999; 56 (4): 475-480.
[26]	Guttuso T Jr. Gabapentin's anti-nausea and anti-emetic effects: A review. Exp Brain Res 2014; 232 (8): 2535-2539.
[27]	Hansen HC. Interstitial cystitis and the potential role of gabapentin. South Med J 2000; 93 (2): 238-242.
[28]	Antonio C, Giovanni P, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacology 2006; 29 (4): 206-214.
[29]	Rayner H, Baharani J, Smith S, Suresh V, Dasgupta I. Uraemic pruritis: Relief of itching by gabapentin and pregabalin. Nephron Clin Pract 2012; 122: 75-79.
[30]	Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomized, double-blind, placebo-controlled trial. Lancet 2012; 380 (9853): 1583-1589.
[31]	Menon M. Gabapentin in the treatment of persistent hiccups in advanced malignancy. Indian J Palliat Care 2012; 18 (2): 138-140.
[32]	Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994 Sep; 55 Suppl B: 47-52.
[33]	Clozapine mechanism of action. https: //psychscenehub.com/psychpedia/clozapine-mechanism-of-action/.
[34]	Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol. 2005 May; 20 (3): 179-81.
[35]	Binder MR. FLASH syndrome: Tapping into the root of chronic illness. AJCEM 2020; 8 (6): 101-109.
[36]	Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: A randomized controlled trial. JAMA Intern Med 2014; 174 (1): 70-77.
[37]	Salehi M, Kheirabadi GR, Maracy MR, Ranjkesh M. Importance of gabapentin dose in treatment of opioid withdrawal. J Clin Psychopharmacol 2011; 31 (5): 593-596.
[38]	Sanders NC, Mancino MJ, Gentry WB, et al. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol 2013; 21 (4): 294-302.
[39]	Mariani JJ, Malcolm RJ, Mamczur AK, et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. Am J Drug Alcohol Abuse 2016; 42 (3): 333-340.
[40]	Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal, and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012; 37 (7): 1689–1698.
[41]	Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: Current science and future outlook. Pharmacotherapy 2016; 36 (5): 511-535.
[42]	Bisaga A, Aharonovich E, Garawi F, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006; 28; 81 (3): 267-274.
[43]	Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: A case series. J Clin Psychiatry 2001; 62 (1): 19-23.
[44]	Gentry JR, Hill C, Malcolm R. New anticonvulsants: A review of applications for the management of substance abuse disorders. Ann Clin Psychiatry 2002; 14 (4): 233-245.
[45]	Urschel HC 3rd, Hanselka LL, Gromov I, White L, Baron M. Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence. Mayo Clin Proc 2007; 82 (10): 1170-1178.
[46]	Slavova S, Miller A, Bunn TL, et al. Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend 2018; 186: 80–85.
[47]	Eroglu C, Allen NJ, Susman MW, et al. The gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009; 139 (3): 380-392.
[48]	Sorrells SF, Paredes MF, Cebrian-Silla A, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature 2018; 555: 377-381.
[49]	Fujii H, Goel A, Bernard N, et al. Pregnancy outcomes following gabapentin use. Neurology 2013; (80): 1565-1570.
[50]	Patorno E, Bonn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303 (14): 1401-1409.
[51]	Vollmer KO, Anhut H, Thomann P, Wagner F, Jancken D. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. Advances in Epileptology 1989; 17: 209-211.
[52]	Middleton O. Suicide by gabapentin overdose. J Forensic Sci 2011; 56 (5): 1373-1375.
[53]	Cantrell FL, Mena O, Gary RD, McIntyre IM. An acute gabapentin fatality: A case report with postmortem concentrations. Int J Legal Med 2015; 129 (4): 771-775.
[54]	DPhil LL, DPhil OCG, DPhil ZM, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: A population-based cohort study. Lancet 2017; 300 (10093): 490-499.
[55]	Agrawal S, Khazaeni B. Acetaminophen toxicity. StatPearls [Internet]. Last update: August 1, 2022.
[56]	Dinwiddie AT, Tanz LJ, Bitting J. Morbidity and mortality weekly report 2022; 71 (41); 1308–1310.
[57]	GoodRx: Top 10 prescription drugs in the U.S., Published November, 2021.
[58]	Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. Am J Psychiatry 2015; 172 (5): 487-488.
[59]	Reccoppa L, Malcolm R, Ware M. Gabapentin abuse in inmates with prior history of cocaine dependence. Am J Addict 2004; 13 (3): 321-323.
[60]	Pierre JM, Shnayder I, Wirshing DA, Wirshing WC. Intranasal quetiapine abuse. Am J Psychiatry 2004; 161 (9): 1718.
[61]	Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ("Q-ball"). Am J Psychiatry 2007; 164 (1): 173-174.
[62]	Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry 2007; 164 (1): 174-175.
[63]	Fischer BA, Boggs DL. The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature. Neuroscience & Biobehavioral Reviews 2010 Mar 31; 34 (4): 555-558.
[64]	Del Paggio D. Psychotropic medication abuse by inmates in correctional facilities. Mental Health Clinician 2012; 1 (8): 187–188.
[65]	Bronson J, Berzofsky M. U.S. Department of Justice special report: Indicators of mental health problems reported by prisoners and jail inmates, 2011-2012.
[66]	Binder MR. Gabapentin—The popular but controversial anticonvulsant drug may be zeroing in on the pathophysiology of disease. AJCEM 2021; 9 (4): 122-134.
[67]	Binder MR. Anticonvulsants: The psychotropic and medically protective drugs of the future. AJCEM 2021; 9 (5): 180-188.
[68]	Binder MR. Psychiatric and functional physical symptoms: the more telling “fifth” vital sign. AJCEM 2021; 9 (6): 233-237.
[69]	Binder MR. Neuronal hyperexcitability: The elusive but modifiable instigator of disease. AJCEM 2022; 10 (1): 1-7.
[70]	Binder MR. A pathophysiolgically-based approach to the treatment and prevention of mental illness and its related disorders. AJCEM 2021; 9 (6): 223-232.
[71]	Binder MR. Focused neuroregulation in the treatment and prevention of mental and physical illness. AJCEM 2022; 10 (2): 49-58.
[72]	Neuronal hyperexcitability: The elusive link between social dysfunction and biological dysfunction. World Journal of Public Health 2022; 7 (3): 99-110.

Cite This Article

Plain Text BibTeX RIS

APA Style

Michael Raymond Binder. (2022). Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities. American Journal of Internal Medicine, 10(6), 114-121. https://doi.org/10.11648/j.ajim.20221006.11

Copy | Download

ACS Style

Michael Raymond Binder. Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities. Am. J. Intern. Med. 2022, 10(6), 114-121. doi: 10.11648/j.ajim.20221006.11

Copy | Download

AMA Style

Michael Raymond Binder. Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities. Am J Intern Med. 2022;10(6):114-121. doi: 10.11648/j.ajim.20221006.11

Copy | Download

@article{10.11648/j.ajim.20221006.11,
  author = {Michael Raymond Binder},
  title = {Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities},
  journal = {American Journal of Internal Medicine},
  volume = {10},
  number = {6},
  pages = {114-121},
  doi = {10.11648/j.ajim.20221006.11},
  url = {https://doi.org/10.11648/j.ajim.20221006.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20221006.11},
  abstract = {The anticonvulsant gabapentin is now one of the most commonly prescribed drugs in America. However, after nearly three decades of steady growth in popularity, the drug is becoming as controversial as it is popular. Although gabapentin was initially approved for the adjunctive treatment of partial seizures, its use has gradually expanded to an ever-increasingly number of disorders, including neuropathic pain, restless leg syndrome, generalized anxiety disorder, bipolar disorder, treatment-resistant depression, post-traumatic stress disorder, chronic insomnia, various substance use disorders, chronic insomnia, diabetic neuropathy, postoperative analgesia, tension headache, migraine headache, fibromyalgia, irritable bowel syndrome, hot flashes, essential tremor, nausea and vomiting, interstitial cystitis, overactive bladder, pruritus, chronic cough, and persistent hiccups. However, in addition to its prescription use, gabapentin is now becoming increasingly popular among illicit users, a phenomenon that appears to be the primary basis of the growing controversy around the drug. This article will explore both the benefits and liabilities of gabapentin in an effort to dispel the myths and clarify the facts about the drug. It will also compare the benefits of gabapentin to other anticonvulsants, analgesics, and psychotropic drugs in an effort to arrive at a more accurate risk-benefit assessment of gabapentin’s use. With an ever-increasing amount of information being uploaded to the internet, it is especially important for those who have the most experience prescribing and researching gabapentin to tease out the misinformation and provide the medical community and the public with the most accurate possible understanding of the drug. Only then will we be able to take the greatest advantage and avoid the most harm in relation to this inexpensive and widely-prescribed pharmacological resource. Those interested in addition evidence-based information on gabapentin are directed to the article, Gabapentin: The Popular but Controversial Anticonvulsant Drug May Be Zeroing in on the Pathophysiology of Disease.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities
AU  - Michael Raymond Binder
Y1  - 2022/11/10
PY  - 2022
N1  - https://doi.org/10.11648/j.ajim.20221006.11
DO  - 10.11648/j.ajim.20221006.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 114
EP  - 121
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20221006.11
AB  - The anticonvulsant gabapentin is now one of the most commonly prescribed drugs in America. However, after nearly three decades of steady growth in popularity, the drug is becoming as controversial as it is popular. Although gabapentin was initially approved for the adjunctive treatment of partial seizures, its use has gradually expanded to an ever-increasingly number of disorders, including neuropathic pain, restless leg syndrome, generalized anxiety disorder, bipolar disorder, treatment-resistant depression, post-traumatic stress disorder, chronic insomnia, various substance use disorders, chronic insomnia, diabetic neuropathy, postoperative analgesia, tension headache, migraine headache, fibromyalgia, irritable bowel syndrome, hot flashes, essential tremor, nausea and vomiting, interstitial cystitis, overactive bladder, pruritus, chronic cough, and persistent hiccups. However, in addition to its prescription use, gabapentin is now becoming increasingly popular among illicit users, a phenomenon that appears to be the primary basis of the growing controversy around the drug. This article will explore both the benefits and liabilities of gabapentin in an effort to dispel the myths and clarify the facts about the drug. It will also compare the benefits of gabapentin to other anticonvulsants, analgesics, and psychotropic drugs in an effort to arrive at a more accurate risk-benefit assessment of gabapentin’s use. With an ever-increasing amount of information being uploaded to the internet, it is especially important for those who have the most experience prescribing and researching gabapentin to tease out the misinformation and provide the medical community and the public with the most accurate possible understanding of the drug. Only then will we be able to take the greatest advantage and avoid the most harm in relation to this inexpensive and widely-prescribed pharmacological resource. Those interested in addition evidence-based information on gabapentin are directed to the article, Gabapentin: The Popular but Controversial Anticonvulsant Drug May Be Zeroing in on the Pathophysiology of Disease.
VL  - 10
IS  - 6
ER  -

Copy | Download

Author Information

Michael Raymond Binder

767 Park Avenue West, Suite 210, Highland Park, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Michael Raymond Binder. (2022). Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities. American Journal of Internal Medicine, 10(6), 114-121. https://doi.org/10.11648/j.ajim.20221006.11

Copy | Download

ACS Style

Michael Raymond Binder. Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities. Am. J. Intern. Med. 2022, 10(6), 114-121. doi: 10.11648/j.ajim.20221006.11

Copy | Download

AMA Style

Michael Raymond Binder. Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities. Am J Intern Med. 2022;10(6):114-121. doi: 10.11648/j.ajim.20221006.11

Copy | Download

@article{10.11648/j.ajim.20221006.11,
  author = {Michael Raymond Binder},
  title = {Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities},
  journal = {American Journal of Internal Medicine},
  volume = {10},
  number = {6},
  pages = {114-121},
  doi = {10.11648/j.ajim.20221006.11},
  url = {https://doi.org/10.11648/j.ajim.20221006.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20221006.11},
  abstract = {The anticonvulsant gabapentin is now one of the most commonly prescribed drugs in America. However, after nearly three decades of steady growth in popularity, the drug is becoming as controversial as it is popular. Although gabapentin was initially approved for the adjunctive treatment of partial seizures, its use has gradually expanded to an ever-increasingly number of disorders, including neuropathic pain, restless leg syndrome, generalized anxiety disorder, bipolar disorder, treatment-resistant depression, post-traumatic stress disorder, chronic insomnia, various substance use disorders, chronic insomnia, diabetic neuropathy, postoperative analgesia, tension headache, migraine headache, fibromyalgia, irritable bowel syndrome, hot flashes, essential tremor, nausea and vomiting, interstitial cystitis, overactive bladder, pruritus, chronic cough, and persistent hiccups. However, in addition to its prescription use, gabapentin is now becoming increasingly popular among illicit users, a phenomenon that appears to be the primary basis of the growing controversy around the drug. This article will explore both the benefits and liabilities of gabapentin in an effort to dispel the myths and clarify the facts about the drug. It will also compare the benefits of gabapentin to other anticonvulsants, analgesics, and psychotropic drugs in an effort to arrive at a more accurate risk-benefit assessment of gabapentin’s use. With an ever-increasing amount of information being uploaded to the internet, it is especially important for those who have the most experience prescribing and researching gabapentin to tease out the misinformation and provide the medical community and the public with the most accurate possible understanding of the drug. Only then will we be able to take the greatest advantage and avoid the most harm in relation to this inexpensive and widely-prescribed pharmacological resource. Those interested in addition evidence-based information on gabapentin are directed to the article, Gabapentin: The Popular but Controversial Anticonvulsant Drug May Be Zeroing in on the Pathophysiology of Disease.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Illicit Use of Gabapentin May Reveal More About the Drug’s Benefits Than Its Liabilities
AU  - Michael Raymond Binder
Y1  - 2022/11/10
PY  - 2022
N1  - https://doi.org/10.11648/j.ajim.20221006.11
DO  - 10.11648/j.ajim.20221006.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 114
EP  - 121
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20221006.11
AB  - The anticonvulsant gabapentin is now one of the most commonly prescribed drugs in America. However, after nearly three decades of steady growth in popularity, the drug is becoming as controversial as it is popular. Although gabapentin was initially approved for the adjunctive treatment of partial seizures, its use has gradually expanded to an ever-increasingly number of disorders, including neuropathic pain, restless leg syndrome, generalized anxiety disorder, bipolar disorder, treatment-resistant depression, post-traumatic stress disorder, chronic insomnia, various substance use disorders, chronic insomnia, diabetic neuropathy, postoperative analgesia, tension headache, migraine headache, fibromyalgia, irritable bowel syndrome, hot flashes, essential tremor, nausea and vomiting, interstitial cystitis, overactive bladder, pruritus, chronic cough, and persistent hiccups. However, in addition to its prescription use, gabapentin is now becoming increasingly popular among illicit users, a phenomenon that appears to be the primary basis of the growing controversy around the drug. This article will explore both the benefits and liabilities of gabapentin in an effort to dispel the myths and clarify the facts about the drug. It will also compare the benefits of gabapentin to other anticonvulsants, analgesics, and psychotropic drugs in an effort to arrive at a more accurate risk-benefit assessment of gabapentin’s use. With an ever-increasing amount of information being uploaded to the internet, it is especially important for those who have the most experience prescribing and researching gabapentin to tease out the misinformation and provide the medical community and the public with the most accurate possible understanding of the drug. Only then will we be able to take the greatest advantage and avoid the most harm in relation to this inexpensive and widely-prescribed pharmacological resource. Those interested in addition evidence-based information on gabapentin are directed to the article, Gabapentin: The Popular but Controversial Anticonvulsant Drug May Be Zeroing in on the Pathophysiology of Disease.
VL  - 10
IS  - 6
ER  -

Copy | Download